SynthesisHuman vaccines & immunotherapeutics2022
Burden of vaccine-preventable diseases among at-risk adult populations in the US.
Synthesis in Human vaccines & immunotherapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Pooled it
- Guidelines on Immunization of People with Chronic Neurological Disorders: A Systematic Review.Vaccines · 2026Review
- Uptake of Influenza, Pneumococcal, and COVID-19 Vaccines Among People Living with HIV: Findings from the Ontario HIV Treatment Network Cohort Study.AIDS and behavior · 2026Article
- Article
- Adult vaccination in people living with HIV attending a tertiary centre infectious diseases clinic.Southern African journal of HIV medicine · 2026Article
- Neonatal tetanus in undocumented migrant families in Saudi Arabia: outcomes and critical care resource utilization in a 10-year tertiary PICU cohort.Frontiers in pediatrics · 2026Article
- Preferences for and drivers of adult vaccination clinic site selection: A cross-sectional study in 30 provinces in China.Human vaccines & immunotherapeutics · 2025Article
- Perspectives of healthcare professionals on the pharmacist's role in delivering vaccinations for patients with cancer: a qualitative study using role theory.International journal of clinical pharmacy · 2025Article
- Burden of Pneumococcal Disease and Adult Vaccination Landscape: An Overview with Data and Policy Insights from Türkiye.Infectious diseases & clinical microbiology · 2025Review
- Multidisciplinary perspective on a pharmacist-led vaccination clinic in a regional cancer care setting: A qualitative study.Exploratory research in clinical and social pharmacy · 2025Article
- Vaccine hesitancy in patients with solid tumors: a cross-sectional single-center survey.BMC public health · 2024Article
- Burden of vaccine-preventable diseases in adults (50+) in the United States: a retrospective claims analysis.BMC public health · 2024Observational
- Review
- Article
- Article
- Societal Cost of Racial Pneumococcal Disease Disparities in US Adults Aged 50 Years or Older.Applied health economics and health policy · 2024Article
- Assessment of Disease Burden and Immunization Rates for Vaccine-Preventable Diseases in People Living with HIV: The Korea HIV/AIDS Cohort Study.Infection & chemotherapy · 2023Article
- Understanding Factors Contributing to Vaccine Hesitancy in a Large Metropolitan Area.Vaccines · 2023Article
- Review of the unmet medical need for vaccination in adults with immunocompromising conditions: An Indian perspective.Human vaccines & immunotherapeutics · 2023Review
Corrections and comments
- Commented on by
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Life-course immunization holds significant benefit for population health by reducing the burden of vaccine-preventable diseases (VPD) through vaccinating individuals at different stages and circumstances in life. The study aimed to determine the epidemiologic, clinical, economic, and societal burden of VPDs among at-risk adult subpopulations in the United States. A systematic literature review was conducted for articles published between January 2010 and June 2020, which identified 72 publications. There was heterogeneity in available epidemiology data, with the prevalence of VPDs ranging from 1.1% to 68.7%. Where the disease burden was described, outcomes were typically worse among high-risk subpopulations than in the general population. Several VPDs, including herpes zoster, meningococcal, and pneumococcal infections were associated with increased costs. This review suggests that subpopulations may not frequently interact with the healthcare system, or their risk factors may not be recognized by healthcare providers, and therefore individuals may not be appropriately targeted for vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.